At BIO 2026, biotech leadership tied U.S. biotech competitiveness directly to patient access and national security, arguing that outdated regulation and funding gaps could erode U.S. leadership. Biotechnology Innovation Organization (BIO) VP Kelly Seagraves said public-private coordination is needed to ensure the regulatory framework can absorb innovations coming from ARPA-H and other initiatives. Caitlin Frazer, executive director of the National Security Commission on Emerging Biotechnology (NSCEB), urged implementation of commission recommendations and emphasized government readiness to evaluate regulatory frameworks supporting rapid innovation in national interest contexts. The messaging frames clinical development acceleration and policy modernization as core elements for both health systems and biothreat response capacity. (Article references: BIO 2026 executive remarks on policy and national security.)